Overview

Efficacy, Safety, and Tolerability of Eluxadoline in the Treatment of Participants With Diarrhea-Predominant Irritable Bowel Syndrome (IBS-d)

Status:
Completed

Trial end date:
2014-07-29

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine the efficacy, safety, and tolerability of different doses of eluxadoline (JNJ-27018966) compared with placebo in the treatment of participants with diarrhea-predominant irritable bowel syndrome.

Phase:

Phase 3

Details

Lead Sponsor:

Furiex Pharmaceuticals, Inc

Treatments:

Eluxadoline